Title: Metabolic patterns and seizure outcomes following anterior temporal lobectomy.

Running head: Metabolic patterns and surgical outcomes.

Varduhi Cahill, MD,^{1, 12, 13} Benjamin Sinclair, PhD,^{2,10} Charles B Malpas, PhD,^{1,4,5,10} Anne M McIntosh, PhD,^{1,3,10} Zhibin Chen, PhD,^{1,10} Lucy E Vivash, PhD,^{1,10} Marie F O'Shea, PhD,⁶ Sarah J Wilson, PhD,^{5,6} Patricia M Desmond, MD,² Salvatore U Berlangieri, MBBS,⁶ Rodney J Hicks, MD,⁷ Christopher C Rowe, MD,^{3,8} Andrew P Morokoff, PhD,⁹ James A King, MBBS,⁹ Gavin C Fabinyi, MBBS,¹⁰ Andrew H Kaye, MD,⁹ Patrick Kwan, MD, PhD,^{1,10} Samuel F Berkovic, MD, FRS,³ Terence J O'Brien, MD^{1,10}

¹The Departments of Medicine and Neurology, The Melbourne Brain Centre, The University of Melbourne, The Royal Melbourne Hospital, Melbourne, Australia

²The Departments of Medicine and Radiology, The University of Melbourne, The Royal Melbourne Hospital, Melbourne, Australia

³The Epilepsy Research Centre, The University of Melbourne, The Austin Hospital, Melbourne, Australia

⁴The Murdoch Children's Research Institute, Melbourne, Australia

⁵The Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Australia

⁶The Comprehensive Epilepsy Program, The Austin Hospital, Melbourne, Australia

⁷The Peter MacCallum Centre, The University of Melbourne, Melbourne, Australia

⁸The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia

⁹The Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Melbourne, Australia

¹⁰The Department of Surgery, The University of Melbourne, The Austin Hospital, Melbourne, Australia

¹¹The Departments of Neuroscience and Neurology, The Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Australia

¹² The Manchester Centre for Clinical Neurosciences, Manchester, United Kingdom

¹³ University of Manchester, Manchester, United Kingdom

Title: 69 characters

Abstract: 249 words

Running head: 36 characters

Introduction: 413

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/ana.25405](https://doi.org/10.1002/ana.25405)

Discussion: 795

Total: 3776

Figures: 0

Tables: 8 +1 (Table 9 is Supplementary)

Correspondence to: Professor Terence O'Brien, Department of Neuroscience, Central Clinical School, Monash University, The Alfred Centre, 99 Commercial Road, Melbourne, 3004. E-mail: terence.obrien@monash.edu

Abstract

Objective: We investigated the relationship between the interictal metabolic patterns, the extent of resection of the ^{18}F FDG-PET hypometabolism and seizure outcomes in patients with unilateral drug-resistant mesial temporal lobe epilepsy (MTLE) following anterior temporal lobe resection (ATLR).

Methods: Eighty-two patients with hippocampal sclerosis or normal MRI findings, concordant ^{18}F FDG-PET hypometabolism and at least two years of postoperative follow-up were included in this two-centre study.

The hypometabolic regions in each patient were identified with reference to twenty healthy controls ($p<0.005$). The resected temporal lobe (TL) volume and the volume of resected TL PET hypometabolism (TLH) were calculated from the pre- and postoperative MRI scans co-registered with interictal ^{18}F FDG-PET.

Results: Striking differences in metabolic patterns were observed depending on the lateralisation of the epileptogenic temporal lobe. The extent of the ipsilateral TLH was significantly greater in left MTLE patients ($p<0.001$), whereas right MTLE patients had significantly higher rates of contralateral (CTL) TLH ($p=0.016$). In right MTLE patients, CTL hypometabolism was the strongest predictor of an unfavourable seizure outcome, associated with a five-fold increase in the likelihood of seizure recurrence (OR 4.90, CI:1.07-22.39, $p=0.04$). In left MTLE patients, the greater the extent of the resection of ipsilateral TLH was associated with lower rates of seizure recurrence ($p=0.004$) in univariable analysis, however its predictive value did not reach statistical significance (OR 0.96, CI: 0.90-1.02, $p=0.19$).

Interpretation: The difference in metabolic patterns depending on the lateralisation of MTLE may represent distinct epileptic networks in patients with right vs left MTLE, and can guide preoperative counselling and surgical planning.

1. Introduction

Epilepsy surgery remains the treatment option of choice in patients with drug resistant mesial temporal lobe epilepsy (MTLE). However, despite a thorough multi-modal pre-surgical evaluation, a significant proportion of patients continue having seizures following surgery.^{1,2} Accordingly, the need for reliable predictors of treatment outcomes in this era of personalised medicine remains ongoing. ¹⁸FDG-PET is one of the most established functional imaging modalities employed in the evaluation of epilepsy surgery candidates and offers unique insights into cerebral glucose metabolism at the synaptic level.³⁻⁶ The cost-efficiency of ¹⁸FDG-PET has long been recognised and the wider availability of post-acquisition processing techniques has increased its yield in surgical planning.⁷⁻¹¹

With the advances in EEG and imaging technologies, including multimodal co-registration techniques, the role of ¹⁸FDG-PET in presurgical evaluation has been enhanced beyond being a useful diagnostic tool reserved for the “MRI-negative” cases or clinical scenarios with discordant electro-clinical and structural imaging findings.¹²⁻¹⁶ There has been a growing body of evidence suggesting that the extent of the metabolic compromise correlates with the distribution of ictal EEG discharges.^{17,18} Furthermore, the findings of recent ¹⁸FDG-PET and functional connectivity studies have been convergent in demonstrating the role of ¹⁸FDG-PET as a metabolic biomarker of the extent of the epileptic network dysfunction.^{19,20} It has also been suggested that hypometabolic changes affecting the contralateral (CTL) temporal lobe (TL) may impact on seizure outcomes in patients with drug-resistant MTLE.²¹⁻²⁶ While stereoelectroencephalography (SEEG) and intraoperative imaging co-registration technologies open up new avenues for the use of ¹⁸FDG-PET in surgical planning,^{8,9,27} the studies on how the extent of the resection of ¹⁸FDG-PET hypometabolism affects long-term surgical outcomes have been rather sparse and somewhat contradictory, which could be explained by a modest patient cohort size and methodological differences.^{28,29} Furthermore, the results of functional and metabolic connectivity studies have been suggestive of distinct functional

connectivity patterns depending on the lateralisation of MTLE, including higher rates of CTL TL involvement in patients with right MTLE.^{20, 30-33} The higher rates of bitemporal hypometabolism have been observed in patients with unilateral right MTLE,¹⁹ however the effect of this distinct metabolic pattern on seizure outcomes following the anterior temporal lobe resection (ATLR) has not been demonstrated.

Our study investigated the role of ¹⁸FDG-PET in predicting surgical outcomes in a large, well-characterised cohort of patients with drug-resistant unilateral MTLE. The predictive value of the extent of the resection of ¹⁸FDG-PET hypometabolism and the influence of CTL TL ¹⁸FDG-PET changes on surgical outcomes in patients with right and left MTLE were evaluated.

2. Methods

2.1 Study subjects.

This was a retrospective two-centre study. A total of 82 patients with drug-resistant unilateral MTLE who underwent an ATLR between 2001 and 2014 were included. Patients were identified from the prospectively administered Comprehensive Epilepsy Program databases at the Royal Melbourne and the Austin Hospitals in Melbourne, Australia.

The inclusion criteria were: (1) age ≥ 16 years at the time of surgery, (2) preoperative MRI findings consistent with unilateral hippocampal sclerosis (HS) or no identifiable lesion (“MRI negative”), (3) concordant results of presurgical investigations and seizure semiology, (4) the presence of concordant ipsilateral TL ¹⁸FDG-PET hypometabolism on visual inspection of interictal ¹⁸FDG-PET and (5) at least 2 years of follow up following the ATLR.

The two centres adopted a similar presurgical evaluation protocol, which has been described previously.^{12, 28, 34}

Briefly, this was comprised of at least one five-day period of video-EEG-telemetry including neurological examination, reevaluation of the clinical presentation and seizure semiology, expert neuroradiology review, as well as neuropsychiatric

and neuropsychological assessment. Postoperatively, antiepileptic therapy was commonly rationalised within the first 6-12 months, depending on the seizure outcome. The study was approved by the Melbourne Health and the Austin Health Human Research Ethics Committees.

2.2 Seizure variables and outcomes.

Seizure outcomes were assessed at the time of last follow-up and categorised using Engel's classification of postoperative outcomes as seizure free (Engel's class I) or not seizure free (Engel's class II-IV).³⁵ The duration of follow-up varied between the patients (Table 1) however a minimum of 2 years of postoperative follow-up was achieved for all patients, consistent with the previous published work from our group evaluating predictors of surgical outcomes.³⁴

The "worthwhile improvement" was set at a $\geq 75\%$ reduction in seizure frequency compared to the preoperative seizure burden. Acute seizures occurring within the first week following surgery were discounted.³⁶ Postoperatively, only seizures manifesting with impaired awareness were counted towards seizure recurrence.³⁷

2.3 Neurosurgical Procedure.

All patients underwent a Spencer-type resection, which is a type of ATLR also known as an anteromedial temporal lobectomy or a radical hippocampectomy.³⁸ In brief, it is a two-step procedure involving the resection of the middle temporal gyrus and the inferior temporal gyrus 3-3.5 cm from the tip of the temporal pole, followed by resection of the mesial TL structures including the amygdala, hippocampus and the parahippocampal gyrus. It was the policy of our surgeons to do a less extensive neocortical resection, sparing the superior temporal gyrus, in patients with left (i.e. language dominant) MTLE. This is consistent with the results of previous studies that have reported the smaller volume of temporal lobe resections in patients undergoing left ATLR.^{39, 40}

The adequacy of the hippocampal resection was determined based on a postoperative MRI performed at least three months following surgery.

2.4 ¹⁸FDG-PET and MRI acquisition and post-processing.

Preoperative ¹⁸FDG-PET and MRI examinations were carried out as part of the presurgical evaluation. ¹⁸FDG-PET scans were acquired on a Phillips Allegro (Phillips Medical Systems, Best, The Netherlands) at the Austin Hospital with a voxel size of 2 x 2 x 2mm or a GE Discovery 690 (GE Medical Systems Milwaukee, WI) at the Peter MacCallum Cancer Centre with a voxel size of 1.82 x 1.82 x 3.27mm as described previously.²⁸ The median timing of the ¹⁸FDG-PET scans was 5 months preceding surgery (interquartile range [IQR]: 3-10.25; range 1-23 months).

Until 2005 the MRI examinations were carried out on a Genesis Signa 1.5T (GE Medical Systems Milwaukee, WI), thereafter the scans have been performed on a Magnetom Avanto 1.5T and a Magnetom Trio Tim 3T (Siemens Medical Solutions, Erlangen, Germany). Three-dimensional, T1-weighted, magnetisation prepared rapid acquisition gradient echo sequences were used for post-acquisition processing. All processing was conducted using Statistical Parametric Mapping (SPM) software, version 12 (Wellcome Department of Cognitive Neurology, University College London, London, UK) mounted on a MATLAB R2012-A (MathWorks, Natick, MA, U.S.A.).

¹⁸FDG-PET post-processing.

The images of the patients and 20 healthy controls were reoriented and non-linearly normalised to SPM's built-in PET template using the default parameters within SPM's Old Normalise algorithm including grand mean scaling of 50 and a relative threshold of 0.8. Normalisation parameters were saved for later use. Normalised images were smoothed with an 8 mm full width at half-maximum Gaussian kernel. Hypometabolic regions of the brain were determined with reference to 20 healthy controls of an equivalent age range (16-65). For each patient, a General Linear Model (GLM) was constructed to compare the patient to the 20 controls at each voxel, with a two-sample t-test carried out for each subject. To optimise the detection of the total cerebral ¹⁸FDG-PET SPM hypometabolism (TCH) the modeling was conducted at

every voxel within the whole brain mask (excluding the cerebellum) and a TL mask obtained from the Automated Anatomic Labeling atlas using WFU Pick Atlas toolbox (The Functional MRI Laboratory Wake Forest University School of Medicine).⁴¹ This yielded a t-statistic image for each subject. T-statistic images were first transformed from the space of the PET atlas in which inter-subject comparisons were made and then back to the native space of each patient's ¹⁸FDG-PET using the inverse of the normalisation parameters.

MRI post-processing.

The resected tissue volume was estimated by deriving the difference through matching preoperative and postoperative MRIs. Preoperative and postoperative MRIs were non-linearly registered using SPM's longitudinal registration toolbox with default parameters.⁴² We opted for non-linear registration, since linear registration was not sufficient due to an inaccurate account of the postoperative brain changes, in particular the collapse of the brain tissue into the resection cavity. Preoperative and postoperative images were segmented into grey matter (GM), white matter (WM) and cerebral spinal fluid. The GM and WM partitions were added and thresholded at 0.1, resulting in an image of the brain tissue. A total cerebral volume image was constructed by taking the union of the preoperative and registered postoperative brain segmentations. The resection volume was measured as the difference between the preoperative and postoperative scans. To minimise the contribution of the pre- and postoperative image registration and segmentation errors, the largest cluster of the difference image was selected, which was invariably the resected tissue. To make this selection, the resected tissue was separated from the registration error by eroding the image by two voxels. Subsequently, the now separate resected tissue was selected, and dilated by two voxels to restore it to its original size. All resected tissue images were inspected by two independent operators to ensure the resected region on the postoperative MRI image was filled accurately. The volumes of resected tissue and of the total cerebral volume were calculated by summing the non-zero voxels and multiplying by the voxel size.

Combined MRI and PET post-processing.

To ascertain the extent of the ^{18}F FDG-PET hypometabolism resected, the patient's ^{18}F FDG-PET images were matched to their preoperative MRI. ^{18}F FDG-PET images were linearly co-registered to preoperative MRI using SPM's co-registration algorithm, which utilises normalised mutual information to quantify similarity between two images of different modalities. The co-registered ^{18}F FDG-PET/MRI images were inspected by two independent operators to ensure the adequacy of the co-registration. This co-registration was used to transform the t-statistic images from the native ^{18}F FDG-PET space to the native preoperative MRI space. The t-statistic images were transformed to the preoperative MRI space, were then thresholded (uncorrected $p=0.005$, cluster extent >100 voxels) to elicit the region of hypometabolism and binarised. The optimal level of SPM thresholding was achieved through the identification of parameters whereby the ^{18}F FDG-PET hypometabolism was identifiable in the ipsilateral TL in all patients. Thresholding was undertaken in the MRI space, rather than the PET template space to allow for the application of more accurate interpolation to a continuous image, i.e. the t-statistic image, as opposed to a discontinuous image, i.e. a thresholded t-statistic image. This resulted in a smoother hypometabolism boundary when applying the threshold in the higher resolution MRI space, rather than the low resolution PET template space.

The amount of hypometabolism resected was calculated by masking the hypometabolism image in the MRI space by the resected tissue image. The total amount of hypometabolism was calculated by masking the hypometabolism image by the total cerebral volume image. The number of voxels in these masked images were summed and multiplied by the voxel size to derive the volume of resected TL PET hypometabolism (TLH) and the volume of the TCH.

The proportion of the TLH resected was derived as follows:

$$\% \text{ TLH resected} = (\text{volume of TLH resected} \times 100) / \text{volume of TLH}.$$

The proportion of the resected TCH was calculated as follows:

$$\% \text{ TCH resected} = (\text{volume of TLH resected} \times 100) / \text{volume of TCH}.$$

The proportion that extra-temporal hypometabolism (ETH) constituted within TCH was derived by first estimating the volume of ETH by subtracting TLH volume from TCH volume, followed by:

$$\% \text{ ETH} = (\text{ETH volume} \times 100) / \text{TCH volume}.$$

The SPM thresholded images were also inspected for the boundaries of the ipsilateral ¹⁸FDG-PET hypometabolism and the presence of ETH, including its distribution pattern.

In all patients the ¹⁸FDG-PET SPM hypometabolism identifiable in the ipsilateral TL was confined to the TL region without extension into the neighbouring regions (i.e. fronto-orbital, opercular or the temporo-parieto-occipital junction). The ETH areas were identified in the frontal regions (ipsilateral, contralateral and bilateral) and CTL TL region.

2.5 Statistical Analysis.

Univariable analyses using Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables were performed to first explore the differences in pertinent demographic, seizure, pre and postoperative neuroimaging variables in patients with right vs left MTLE, and subsequently, to explore the differences within the subgroups, depending on seizure outcomes.

Pertinent neuroimaging variables with univariable *p*-value <0.1 were included in multivariable logistic regression to explore the predictive value of neuroimaging variables on seizure outcomes in patients with right and left MTLE, respectively. A two-tailed *p* value of <0.05 was considered statistically significant defined for all tests performed unless specified otherwise. All statistical analyses were performed using IBM SPSS 21.0 (IBM Corp., Armonk, NY).

3. Results

3.1. Patients' characteristics and seizure outcomes.

There were 43 patients with right MTLE and 39 patients with left MTLE with comparable gender composition, the age of epilepsy onset, the epilepsy duration, age at surgery and the duration of postoperative follow up (Table 1).

The median postoperative follow up period in patients with right MTLE was 4 years, ranging from 2 to 10 years, and 5 years in patients with left MTLE, ranging from 2 to 14 years. Preoperative seizure burden did not differ in patients with right and left MTLE ($p=0.98$) (Table 3).

The seizure outcomes, excellent (Engel's class I) vs unfavourable (Engel's class II-IV), did not differ in patients with right and left MTLE ($p=1.00$) with excellent outcomes observed in 30 patients (68.9%) with right MTLE and 28 patients (71.8%) with left MTLE.

The striking differences in the interictal metabolic patterns observed in patients with right and left MTLE are outlined in Table 2. Importantly, the left MTLE patients were observed to have significantly higher rates in the extent of ipsilateral TLH ($p<0.001$), with the markedly higher proportion of TCH being confined to the ipsilateral TL ($p<0.001$). The right MTLE patients had a significantly higher proportion of TCH falling extra-temporally ($p<0.001$), with the preferential CTL TLH occurrence in right MTLE patients ($p=0.003$).

The estimated volumes of resected TL tissue in patients with right MTLE significantly exceeded those in patients with left MTLE ($p<0.001$), in keeping with the commonly employed more sparing approach to ATR in patients with left MTLE.^{39, 43}

3.2 Pre and postoperative imaging variables in relation to seizure outcomes.

Interestingly, the presence of SPM hypometabolism detected outside the ipsilateral TL was common 54/82 (65.9%), however significantly more prevalent in right MTLE patients (33/43, 76.7%, $p=0.037$). The most commonly sighted distributions of hypometabolism outside the ipsilateral TL in patients with right and left MTLE are outlined in Table 4. Hypometabolic changes in frontal regions were common and

comparable in patients with right and left MTLE and were not associated with worse outcomes. The presence of CTL TLH in patients with left MTLE did not influence the rates of seizure freedom, however in the right MTLE cohort it was associated with unfavourable seizure outcomes ($p=0.016$) (Table 5).

In the left MTLE cohort the excellent seizure outcomes were associated with the greater resected TL tissue volumes ($p=0.005$) as well as the greater the extent of resection of ipsilateral TL hypometabolism ($p=0.004$) (Table 6), which resonates with the findings of previous studies.^{28, 44}

While the higher rates of HS on preoperative MRI (86.7% in right MTLE and 96.4% in left MTLE patients) in patients with excellent seizure outcomes were in keeping with previous studies,³⁴ they did not reach statistical significance in influencing seizure outcomes ($p=0.10$ and $p=0.19$ in patients with right and left MTLE, respectively).

3.3 Predictors of seizure outcomes.

The results of the multivariable logistic regression exploring the predictive value of pertinent pre- and postoperative neuroimaging features, focusing on preoperative MRI findings and ¹⁸FDG-PET patterns in right MTLE patients and the extent of both, the TL tissue resection and the ipsilateral TL hypometabolism in the left MTLE group, are shown in Tables 7 and 8, respectively.

In the right MTLE patients, the presence of CTL TLH was the strongest predictor of a heightened risk of unfavourable seizure outcomes and was associated with a nearly five-fold increase in the risk of postoperative seizure recurrence (OR 4.90, 95% confidence interval [CI]: 1.07-22.39, $p=0.04$).

In the left MTLE group, the predictive value of both, the TL resection volume and the extent of the ipsilateral TL hypometabolism resection was explored however neither

of the above predictors reached statistical significance ($p=0.14$ and $p=0.19$, respectively).

The presence of HS on preoperative MRI has long been shown to be an independent predictor of favourable seizure outcomes in patients with drug-resistant MTLE.³⁴ Our results corroborate with the above findings in that 76% of patients with HS on preoperative MRI achieved seizure freedom and only 42% of patients with normal MRI brain findings had a favourable outcome. The subgroup analysis of seizure outcome predictors is summarised in Supplementary Table 9. The presence of CTL hypometabolism predicted an unfavourable seizure outcome ($p=0.018$).

4. Discussion

The results of our study demonstrated striking differences in metabolic patterns in patients with right and left MTLE, with significantly greater rates of bitemporal hypometabolic changes observed in patients with right MTLE, whereas the patients with left MTLE had more extensive ipsilateral TL ^{18}F FDG-PET hypometabolism. The studies examining the evolution of the ^{18}F FDG-PET hypometabolism over time have been sparse and mostly focused on paediatric populations. Gaillard *et al* studied the temporal evolution of the ^{18}F FDG-PET changes in a mixed paediatric patient cohort, including a sub-group with drug-resistant epilepsy who were evaluated for epilepsy surgery, over a mean interval of 3 years.⁴⁵ They demonstrated no evidence of hypometabolism progression, with seizure frequency and time since the last seizure being the most important determinants of the differences in regional hypometabolism over the serial scans. In contrast a recent study evaluating the interval changes in ^{18}F FDG-PET hypometabolism in a heterogeneous group of paediatric patients with drug-resistant epilepsy did find progression in the PET hypometabolism over time, with the median interval between the scans being over 4 years, in particular in patients with ongoing drug resistant seizures.⁴⁶ In some of these cases unilateral hypometabolism evolved into bilateral hypometabolism on the subsequent scans. In our study, the homogeneity of our cohort and the timing of the ^{18}F FDG-PET scans,

with the median being 5 months preceding surgery, substantially diminishes the possibility of dynamic changes influencing the findings. However, the possibility of interval changes cannot be excluded completely.

Remarkably, our findings resonate with the results of functional and metabolic connectivity studies,^{20, 30, 32, 33, 47} demonstrating evidence of altered connectivity patterns in patients with MTLE, depending on the lateralisation. In addition, while it remains unknown whether or not metabolic and functional asymmetry share the same underlying mechanisms our findings corroborate with the results of Magnetic Resonance Spectroscopy studies by Zubler *et al.*,⁴⁸ who demonstrated widespread abnormalities, with the involvement of CTL TL, in patients with right MTLE. It is not inconceivable, in light of the growing body of evidence demonstrating distinct aberrant metabolic and connectivity patterns, depending on the MTLE lateralisation, that the right and left MTLE may represent two different entities where further research may not only advance our understanding of epileptogenesis but also influence patient management.

Our findings have shown that the overall extent of the ETH and hypometabolic changes in the frontal regions was not associated with adverse seizure outcomes, regardless of the MTLE lateralisation and may represent changes associated with seizure propagation pathways.⁴⁹

Conversely, in right MTLE patients the presence of CTL TLH heralded unfavourable seizure outcomes, heightening the risk of postoperative seizure recurrence five-fold. While the association of poor seizure outcomes in patients with unilateral MTLE and bitemporal hypometabolism has been reported previously,²¹⁻²⁶ with Joo *et al.* reporting higher rates of non-lateralising EEG patterns in patients with bitemporal hypometabolism.²¹

We found that the patients with right MTLE had higher rates of CTL TL hypometabolism and to our knowledge, it has not been described previously in conjunction with the lateralisation of MTLE.

Within the limitations of the current study, we therefore propose that it is not the extent but the location of the ETH, which is the ultimate determinant of unfavourable seizure outcomes.

Interestingly, in the left MTLE cohort, the greater TL resection volume was associated with excellent seizure outcomes and so was the greater the extent of resected ipsilateral TL ^{18}FDG -PET hypometabolism, in keeping with previous studies,^{28, 44} albeit none of these potential predictors reached statistical significance. It has been proposed that the extent of ^{18}FDG -PET hypometabolism is a metabolic biomarker of the extent of neural network dysfunction in patients with MTLE.^{19, 28, 50, 51} It might be, in light of potentially distinct networks implicated in right vs left MTLE, that neuronal dysfunction in left MTLE patients tends to be more confined within the ipsilateral TL and further studies looking into the influence of the extent of resection of the ipsilateral TL ^{18}FDG -PET hypometabolism would be warranted with the focus on the left MTLE cohort.

Moreover, it has been shown that the greater TL resection volumes were associated with favourable seizure outcomes on several occasions,^{44, 52} and yet, the quest for the optimal volume of TL resection remains ongoing to this day.⁵³ In reality, the left ATLRe procedures tend to be more sparing with the left superior temporal gyrus being commonly preserved, resulting in a less extensive TL resection in left MTLE patients.^{39, 43} Our findings demonstrate distinct metabolic patterns with more extensive ipsilateral TL involvement in left MTLE patients and preferential CTL involvement in patients with right MTLE, which may help to explain the disparity between the extent of the TL resection volume and the seizure freedom rates. Further studies are warranted to explore the potential value of ^{18}FDG -PET tailored resections in patients with left MTLE.

5. Conclusions

Our findings, demonstrate striking differences in the metabolic patterns in patients with right vs left MTLE and offer further insights into potentially distinct epileptogenic network dysfunction, depending on the lateralisation of the MTLE.

From a practical standpoint, our findings call for the extended role of ^{18}F FDG-PET in presurgical planning. Current guidelines reserve the use of ^{18}F FDG-PET for “MRI-negative” cases and for the patients with discordant MRI and electro-clinical findings. With the results of our study demonstrating CTL TH being a strong predictor of unfavourable seizure outcomes heralding a five-fold increase in seizure recurrence in patients with right MTLE, the wider use of ^{18}F FDG-PET can influence stratification of surgical candidates and improve presurgical counselling, in line with the expectations of personalised patient care.

Acknowledgements

This study was supported by the Melbourne International Research Scholarship and the Melbourne International Fee Remission Scholarship (V.C.).

We thank Mr Jason Callaghan, Mr Graeme O’Keefe and Mr Christopher Stewart for their assistance in the retrieval of the PET and MRI scans.

Authors Contributions

V.C., T.J.O., P.K., S.F.B., B.S., A.M. M. contributed to the concept and study design
V.C., B.S., Z.C., A.M. M., S.F.B., C.B.M., M.F.O., S.U.B., S.J.W., R.J.H., A.H.K., J.A.K., A.P.M., C.C.R., P.M.D., G.C.F. contributed to the data acquisition and analysis.

V.C., T.J.O., P.K. drafted the manuscript and figures. All authors approved the final version.

Potential Conflicts of Interest

Nothing to report.

References

1. McIntosh AM, Wilson SJ, Berkovic SF. Seizure outcome after temporal lobectomy: current research practice and findings. *Epilepsia*. 2001 Oct;42(10):1288-307.

2. Tellez-Zenteno JF, Hernandez Ronquillo L, Moien-Afshari F, Wiebe S. Surgical outcomes in lesional and non-lesional epilepsy: a systematic review and meta-analysis. *Epilepsy Res.* 2010 May;89(2-3):310-8.
3. Willmann O, Wennberg R, May T, Woermann FG, Pohlmann-Eden B. The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy A meta-analysis. *Seizure.* 2007 Sep;16(6):509-20.
4. Knowlton RC. The role of FDG-PET, ictal SPECT, and MEG in the epilepsy surgery evaluation. *Epilepsy Behav.* 2006 Feb;8(1):91-101.
5. Duncan JS, Winston GP, Koepp MJ, Ourselin S. Brain imaging in the assessment for epilepsy surgery. *The Lancet Neurology.* 2016;15(4):420-33.
6. Gaillard WD, Cross JH, Duncan JS, Stefan H, Theodore WH, Task Force on Practice Parameter Imaging Guidelines for International League Against Epilepsy CfD. Epilepsy imaging study guideline criteria: commentary on diagnostic testing study guidelines and practice parameters. *Epilepsia.* 2011 Sep;52(9):1750-6.
7. O'Brien TJ, Miles K, Ware R, Cook MJ, Binns DS, Hicks RJ. The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy. *J Nucl Med.* 2008 Jun;49(6):931-7.
8. Murphy M, O'Brien TJ, Morris K, Cook MJ. Multimodality image-guided epilepsy surgery. *J Clin Neurosci.* 2001 Nov;8(6):534-8.
9. Zhang J, Liu W, Chen H, et al. Multimodal neuroimaging in presurgical evaluation of drug-resistant epilepsy. *Neuroimage Clin.* 2014;4:35-44.
10. Whiting P GR, Burch J, et al. . A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. *Health Technol Assess* 2006;10:1-250, iii-iv.
11. Rathore C, Dickson JC, Teotonio R, Ell P, Duncan JS. The utility of 18F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery. *Epilepsy Res.* 2014 Oct;108(8):1306-14.
12. Carne RP, O'Brien TJ, Kilpatrick CJ, et al. MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome. *Brain.* 2004 Oct;127(Pt 10):2276-85.
13. Neuroimaging Subcommission of the International League Against Epilepsy. Commission on diagnostic strategies: recommendations for functional neuroimaging of persons with epilepsy. *Epilepsia.* 41:1350-6.
14. Knowlton RC, Elgavish RA, Limdi N, et al. Functional imaging: I. Relative predictive value of intracranial electroencephalography. *Ann Neurol.* 2008 Jul;64(1):25-34.
15. Pittau F, Grouiller F, Spinelli L, Seeck M, Michel CM, Vulliemoz S. The role of functional neuroimaging in pre-surgical epilepsy evaluation. *Front Neurol.* 2014;5:31.
16. LoPinto-Khoury C, Sperling Mr Fau - Skidmore C, Skidmore C Fau - Nei M, et al. Surgical outcome in PET-positive, MRI-negative patients with temporal lobe epilepsy. *Epilepsia.* 2012 Feb;53(2):342-8.

17. Lamarche F, Job AS, Deman P, et al. Correlation of FDG-PET hypometabolism and SEEG epileptogenicity mapping in patients with drug-resistant focal epilepsy. *Epilepsia*. 2016 Dec;57(12):2045-55.
18. Guedj E, Bonini F, Gavaret M, et al. 18FDG-PET in different subtypes of temporal lobe epilepsy: SEEG validation and predictive value. *Epilepsia*. 2015 Mar;56(3):414-21.
19. Chassoux F, Artiges E, Semah F, et al. Determinants of brain metabolism changes in mesial temporal lobe epilepsy. *Epilepsia*. 2016 Jun;57(6):907-19.
20. Vanicek T, Hahn A, Traub-Weidinger T, et al. Insights into Intrinsic Brain Networks based on Graph Theory and PET in right- compared to left-sided Temporal Lobe Epilepsy. *Sci Rep*. 2016 Jun 28;6:28513.
21. Joo EY, Lee EK, Tae WS, Hong SB. Unitemporal vs bitemporal hypometabolism in mesial temporal lobe epilepsy. *Archives of neurology*. 2004 Jul;61(7):1074-8.
22. Choi JY, Kim SJ, Hong SB, et al. Extratemporal hypometabolism on FDG PET in temporal lobe epilepsy as a predictor of seizure outcome after temporal lobectomy. *European journal of nuclear medicine and molecular imaging*. 2003 Apr;30(4):581-7.
23. Wong CH, Bleasel A, Wen L, et al. The topography and significance of extratemporal hypometabolism in refractory mesial temporal lobe epilepsy examined by FDG-PET. *Epilepsia*. 2010 Aug;51(8):1365-73.
24. Kim MA, Heo K, Choo MK, et al. Relationship between bilateral temporal hypometabolism and EEG findings for mesial temporal lobe epilepsy: analysis of 18F-FDG PET using SPM. *Seizure*. 2006 Jan;15(1):56-63.
25. Koutroumanidis M, Hennessy Mj Fau - Seed PT, Seed Pt Fau - Elwes RD, et al. Significance of interictal bilateral temporal hypometabolism in temporal lobe epilepsy. *Neurology*. 2000 May 9;54(9):1811-21.
26. Blum DE, Ehsan T, Dungan D, Karis JP, Fisher RS. Bilateral temporal hypometabolism in epilepsy. *Epilepsia*. 1998 Jun;39(6):651-9.
27. Lee KK, Salamon N. [18F] fluorodeoxyglucose-positron-emission tomography and MR imaging coregistration for presurgical evaluation of medically refractory epilepsy. *AJNR Am J Neuroradiol*. 2009 Nov;30(10):1811-6.
28. Vinton AB, Carne R, Hicks RJ, et al. The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy. *Brain*. 2007 Feb;130(Pt 2):548-60.
29. Stanisic M, Coello C, Ivanovic J, et al. Seizure outcomes in relation to the extent of resection of the perifocal fluorodeoxyglucose and flumazenil PET abnormalities in anteromedial temporal lobectomy. *Acta neurochirurgica*. 2015 Nov;157(11):1905-16.
30. Dupont S, Samson Y, Van de Moortele PF, et al. Bilateral hemispheric alteration of memory processes in right medial temporal lobe epilepsy. *J Neurol Neurosurg Psychiatry*. 2002 Nov;73(5):478-85.

31. Coito A, Genetti M, Pittau F, et al. Altered directed functional connectivity in temporal lobe epilepsy in the absence of interictal spikes: A high density EEG study. *Epilepsia*. 2016 Mar;57(3):402-11.
32. Englot DJ, Konrad PE, Morgan VL. Regional and global connectivity disturbances in focal epilepsy, related neurocognitive sequelae, and potential mechanistic underpinnings. *Epilepsia*. 2016 Oct;57(10):1546-57.
33. Haneef Z, Lenartowicz A, Yeh HJ, Levin HS, Engel J, Jr., Stern JM. Functional connectivity of hippocampal networks in temporal lobe epilepsy. *Epilepsia*. 2014 Jan;55(1):137-45.
34. Berkovic SF, McIntosh Am Fau - Kalnins RM, Kalnins Rm Fau - Jackson GD, et al. Preoperative MRI predicts outcome of temporal lobectomy: an actuarial analysis. *Neurology*. 1995 Jul;45(7):1358-63.
35. Engel J Jr VNP, Rasmussen TB, Ojemann LM. Outcome with respect to epileptic seizures. In: Engel JJ, editor. *Surgical Treatment of the Epilepsies*: New York: Raven Press; 1993. p. 609-21.
36. Malla BR, O'Brien Tj Fau - Cascino GD, Cascino Gd Fau - So EL, et al. Acute postoperative seizures following anterior temporal lobectomy for intractable partial epilepsy. *J Neurosurg*. 1998 Aug;89(2):177-82.
37. McIntosh AM, Kalnins RM, Mitchell LA, Berkovic SF. Early seizures after temporal lobectomy predict subsequent seizure recurrence. *Ann Neurol*. 2005 Feb;57(2):283-8.
38. Fried I. Anatomic temporal lobe resections for temporal lobe epilepsy. *Neurosurg Clin N Am*. 1993 Apr;4(2):233-42.
39. Yogarajah M, Focke NK, Bonelli SB, et al. The structural plasticity of white matter networks following anterior temporal lobe resection. *Brain*. 2010 Aug;133(Pt 8):2348-64.
40. Bonelli SB, Powell RH, Yogarajah M, et al. Imaging memory in temporal lobe epilepsy: predicting the effects of temporal lobe resection. *Brain*. 2010 Apr;133(Pt 4):1186-99.
41. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002 Jan;15(1):273-89.
42. Ashburner J, Ridgway GR. Symmetric diffeomorphic modeling of longitudinal structural MRI. *Front Neurosci*. 2013 Feb 5;6:197.
43. Shamim S, Wiggs E, Heiss J, et al. Temporal lobectomy: resection volume, neuropsychological effects, and seizure outcome. *Epilepsy Behav*. 2009 Oct;16(2):311-4.
44. Thom M, Mathern GW, Cross JH, Bertram EH. Mesial temporal lobe epilepsy: How do we improve surgical outcome? *Ann Neurol*. 2010 Oct;68(4):424-34.
45. Gaillard WD, Weinstein S Fau - Conry J, Conry J Fau - Pearl PL, et al. Prognosis of children with partial epilepsy: MRI and serial 18FDG-PET. *Neurology*. 2007 Feb 27;68(9):655-9.

46. Govil-Dalela T, Kumar A, Behen ME, Chugani HT, Juhasz C. Evolution of lobar abnormalities of cerebral glucose metabolism in 41 children with drug-resistant epilepsy. *Epilepsia*. 2018 Jul;59(7):1307-1315.
47. Coito A, Plomp G, Genetti M, et al. Dynamic directed interictal connectivity in left and right temporal lobe epilepsy. *Epilepsia*. 2015 Feb;56(2):207-17.
48. Zubler F, Seeck M, Landis T, Henry F, Lazeyras F. Contralateral medial temporal lobe damage in right but not left temporal lobe epilepsy: a (1)H magnetic resonance spectroscopy study. *J Neurol Neurosurg Psychiatry*. 2003 Sep;74(9):1240-4.
49. Van Paesschen W, Dupont P Fau - Sunaert S, Sunaert S Fau - Goffin K, Goffin K Fau - Van Laere K, Van Laere K. The use of SPECT and PET in routine clinical practice in epilepsy. *Curr Opin Neurol*. 2007 Apr;20(2):194-202.
50. Chassoux F, Semah F, Bouilleret V, et al. Metabolic changes and electro-clinical patterns in mesio-temporal lobe epilepsy: a correlative study. *Brain*. 2004 Jan;127(Pt 1):164-74.
51. Chassoux F AE, Semah F, Laurent A, Landré E, Turak B, Gervais P, Helal BO, Devaux B. 18F-FDG-PET patterns of surgical success and failure in mesial temporal lobe epilepsy. *Neurology*. 2017;88(11).
52. Joo EY, Han HJ, Lee EK, et al. Resection extent versus postoperative outcomes of seizure and memory in mesial temporal lobe epilepsy. *Seizure*. 2005 Dec;14(8):541-51.
53. Schramm J. Temporal lobe epilepsy surgery and the quest for optimal extent of resection: a review. *Epilepsia*. 2008 Aug;49(8):1296-307.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Table 1. Patients' characteristics.

<i>Variables</i>	Right MTLE	Left MTLE	<i>p</i> value [#]
Gender, male – n (%)	21/43 (48.8)	20/39 (51.3)	1.00
Age of epilepsy onset, years – median (IQR)	17.0 (7.0 – 27.0)	16.0 (4.0 – 26.0)	0.50
Duration of epilepsy, years – median (IQR)	19.0 (11.0 – 31.0)	19.0 (9.0 – 30.0)	0.91
Age at operation, years – median (IQR)	40.0 (29.0 – 46.0)	34.0 (29.0 – 47.0)	0.58
Duration of follow up, years – median (IQR)	4.0 (3.0 – 8.0)	5.0 (2.0 – 8.0)	0.60

Fisher's exact test was used for categorical variables and Mann-Whitney U test was performed for continuous variables.

Table 2. Summary of pre- and postoperative imaging variables in patients with left vs right MTLE/ATLR.

<i>Variables</i>	<i><u>Right MTLE/ATLR</u></i> n=43 (52.4%)	<i><u>Left MTLE/ATLR</u></i> n=39 (47.6%)	<i>p value[#]</i>
HS on preoperative MRI – n (%)	34/43 (79.1)	36/39 (92.3)	0.12
Volume of preop ipsilateral TL SPM hypometabolism, mm ³ – median (IQR)	3.79 x 10 ³ (1.67 x 10 ³ – 6.85 x 10 ³)	9.28 x 10 ³ (3.57 x 10 ³ – 14.58 x 10 ³)	<0.001
% of TCH confined to ipsilateral TL – median (IQR)	29.9 (20.7 – 41.0)	63.0 (49.8 – 73.5)	<0.001
% TCH SPM hypo distributed extra-temporally – median (IQR)	70.1 (59.0 – 79.3)	37.0 (26.4 – 50.2)	<0.001
Presence of contralateral TLH – n (%)	17/43 (39.5)	4/39 (10.3)	0.003
Volume of TL tissue resected, mm ³ – median (IQR)	21.9 x 10 ³ (17.7 x 10 ³ – 28.0 x 10 ³)	15.4 x 10 ³ (11.8 x 10 ³ – 21.3 x 10 ³)	<0.001
% TLH resected – median (IQR)	59.1 (35.9 – 70.9)	36.4 (23.6 – 58.3)	0.008

[#] Fisher's exact test was used for categorical variables and Mann-Whitney U test was performed for continuous variables.

Table 3. Preoperative seizure burden in patients with right (n=43) and left (n=39) MTLE.

Seizure frequency	Right MTLE n (%)	Left MTLE n (%)
4-10/day	2 (4.7)	1 (2.6)
1-3/day	5 (11.6)	3 (7.7)
1-6/week	17 (39.5)	15 (38.5)
1-3/month	16 (37.2)	16 (40.9)
4-11/year	1 (2.3)	3 (7.7)
1-3/year	2 (4.7)	1 (2.6)

Table 4. Distribution of ET hypometabolism and its association with seizure outcomes.

	<u>Right MTLE cohort</u>			<u>Left MTLE cohort</u>		
	Engel's I	Engel's II-IV	<i>p</i> value [#]	Engel's I	Engel's II-IV	<i>p</i> value [#]
ET distribution						
n (%)	30/43 (69.8)	13/43 (30.2)		28/39 (71.8)	11/39 (28.2)	
Ipsilateral frontal	13/30 (43.3)	8/13 (61.5)	0.33	8/28 (28.6)	4/11 (36.4)	0.71
Contralateral frontal	14/30 (46.7)	5/13 (38.5)	0.74	8/28 (28.6)	5/11 (45.5)	0.45
Bilateral frontal	9/30 (30.0)	4/13 (30.8)	1.00	5/28 (17.9)	3/11 (27.3)	0.66
Contralateral TL	8/30 (26.7)	9/13 (69.2)	0.016	2/28 (7.1)	2/11 (18.2)	0.56

[#] Fisher's exact test was used.

Table 5. Pre- and postoperative seizure variables pertinent to seizure outcomes in patients with right MTLE (univariable analyses).

	Engel's I	Engel's II-IV	
	30/43 (69.8%)	13/43 (30.2%)	<i>p</i> value
HS on MRI – n (%)	26/30 (86.7)	8/13 (61.5)	0.10
Estimated MRI volume of resected TL tissue, mm ³ – median (IQR)	22.17 x 10 ³ (18.22 x 10 ³ – 28.03 x 10 ³)	21.08 x 10 ³ (14.99 x 10 ³ – 26.52 x 10 ³)	0.58
Volume of preoperative TLH, mm ³ – median (IQR)	3.62 x 10 ³ (1.70 x 10 ³ – 7.47 x 10 ³)	3.94 x 10 ³ (1.40 x 10 ³ – 6.16 x 10 ³)	0.94
% TLH resected – median (IQR)	58.67 (35.92 – 73.01)	60.26 (45.98 – 65.27)	0.63
% of TCH confined to ipsilateral TL – median (IQR)	30.72 (22.92 – 42.09)	24.81 (14.55 – 36.35)	0.17
% TCH distributed in ET regions – median (IQR)	69.28 (57.91 – 77.08)	75.19 (63.65 – 85.45)	0.17
Patients with contralateral TLH – n (%)	8/30 (26.7)	9/13 (69.2)	0.016

Table 6. Pre- and postoperative seizure variables pertinent to seizure outcomes in patients with left MTLE (*univariable analyses*).

	Engel's I	Engel's II-IV	
	28/39 (71.8%)	11/39 (28.2%)	<i>p</i> value
HS on MRI – n (%)	27/28 (96.4)	9/11 (81.8)	0.19
Estimated MRI volume of resected TL tissue, mm ³ – median (IQR)	17.78 x10 ³ (12.89 x 10 ³ – 22.95 x 10 ³)	11.78 x10 ³ (8.84 x10 ³ – 14.56 x 10 ³)	0.005
Volume of preoperative TLH, mm ³ – median (IQR)	9.75 x10 ³ (4.60 x 10 ³ – 14.73 x 10 ³)	8.33 x10 ³ (3.57 x 10 ³ – 11.42 x 10 ³)	0.83
% TLH resected – median (IQR)	46.22 (31.29 – 60.30)	24.06 (18.01 – 29.42)	0.004
% of TCH confined to ipsilateral TL – median (IQR)	63.31 (51.03 – 74.15)	62.06 (49.82 – 69.77)	0.62
% TCH distributed in ET regions – median (IQR)	36.69 (25.85 – 48.97)	37.94 (30.23 – 50.18)	0.62
Patients with contralateral TLH – n (%)	2/28 (7.1)	2/11 (18.2)	0.56

Table 7. Predictors of postoperative seizure recurrence in right MTLE patients.

<i>Variables</i>	<i>OR</i>	<i>95% CI</i>	<i>p value</i>
MRI findings (HS vs HS-negative)	2.13	0.39-11.73	0.38
Presence of CTL hypometabolism	4.90	1.07-22.39	0.04

Table 8. Predictors of postoperative seizure recurrence in left MTLE patients.

<i>Variables</i>	<i>OR</i>	<i>95% CI</i>	<i>p value</i>
Estimated MRI volume of resected TL tissue, mm ³	1.00	1.00-1.00	0.14
% TLH resected	0.96	0.90-1.02	0.19

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Cahill, V;Sinclair, B;Malpas, CB;McIntosh, AM;Chen, Z;Vivash, LE;O'Shea, MF;Wilson, SJ;Desmond, PM;Berlangieri, SU;Hicks, RJ;Rowe, CC;Morokoff, AP;King, JA;Fabinyi, GC;Kaye, AH;Kwan, P;Berkovic, SF;O'Brien, TJ

Title:

Metabolic patterns and seizure outcomes following anterior temporal lobectomy

Date:

2019-02-01

Citation:

Cahill, V., Sinclair, B., Malpas, C. B., McIntosh, A. M., Chen, Z., Vivash, L. E., O'Shea, M. F., Wilson, S. J., Desmond, P. M., Berlangieri, S. U., Hicks, R. J., Rowe, C. C., Morokoff, A. P., King, J. A., Fabinyi, G. C., Kaye, A. H., Kwan, P., Berkovic, S. F. & O'Brien, T. J. (2019). Metabolic patterns and seizure outcomes following anterior temporal lobectomy. ANNALS OF NEUROLOGY, 85 (2), pp.241-250. <https://doi.org/10.1002/ana.25405>.

Persistent Link:

<http://hdl.handle.net/11343/285294>